TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Часто задаваемые вопросы
В каком секторе работает TaiMed Biologics (4147)?
TaiMed Biologics относится к сектору Здравоохранение.
Какова текущая цена акций TaiMed Biologics (4147)?
По последним данным, цена акций TaiMed Biologics составляет 61,10 NT$, предыдущее закрытие — 61,10 NT$.
Выплачивает ли TaiMed Biologics (4147) дивиденды?
Нет, TaiMed Biologics не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у TaiMed Biologics (4147)?
У компании TaiMed Biologics бета -0.165, что указывает на более низкую волатильность по сравнению с рынком в целом.
